Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 369Carcinoma, Non-Small-Cell Lung 315Neoplasms 289Prostatic Neoplasms 245Colorectal Neoplasms 214Multiple Myeloma 182Lung Neoplasms 170Neoplasm Metastasis 152Leukemia, Myeloid, Acute 137Pancreatic Neoplasms 130Squamous Cell Carcinoma of Head and Neck 127Ovarian Neoplasms 117Melanoma 98Carcinoma, Renal Cell 94Recurrence 87Stomach Neoplasms 81Precursor Cell Lymphoblastic Leukemia-Lymphoma 80Carcinoma, Hepatocellular 80Lymphoma, Non-Hodgkin 79Head and Neck Neoplasms 79Lymphoma 78Glioblastoma 78Triple Negative Breast Neoplasms 76Lymphoma, Large B-Cell, Diffuse 75Urinary Bladder Neoplasms 69Endometrial Neoplasms 68Brain Neoplasms 68Leukemia, Lymphocytic, Chronic, B-Cell 65Uterine Cervical Neoplasms 62Lymphoma, Follicular 62

Interventions

iadademstat 1decitabine and cedazuridine drug combination 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thrombocythemia, Essential × 30 days × Clear all
NCT06661915 2026-05-13

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Recruiting
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡